Assets
Every drug candidate we track, who holds its European rights, and where it stands.
No European partner disclosed
4 commercial psychedelic assets in European trials have no European licence or partner in their filings.
- COMP360Compass PathwaysPhase 3 complete (COMP005, COMP006)Rights: Compass Pathways plcFiling2026-08-25
- DT120 (registry title MM120)Definium TherapeuticsPhase 3 across four trialsRights: Definium Therapeutics, Inc.Filing2026-09-15
- HLP003Helus PharmaPhase 3: APPROACH (NCT06564818Rights: Cybin Inc.Filing2026-08-24
- GH001GH ResearchPhase 2b completeRights: GH Research PLCFiling2026-08-25
When one of these changes, the Tuesday issue says so.
- BPL-0036 trialsPhase 2b complete
- brenipatide (LY3537031)17 trialsPhase 3 in MDD (two pivotals) and alcohol use disorder (two pivotals)
- COMP3604 trialsPhase 3 complete (COMP005, COMP006)
- DT120 (registry title MM120)5 trialsPhase 3 across four trials
- GH0016 trialsPhase 2b complete
- HLP0034 trialsPhase 3: APPROACH (NCT06564818, US only) COMPLETED on ClinicalTrials.gov, primary completion 2026-09-04 ACTUAL, study completion 2026-10-23 ACTUAL, 223 enrolled, no results posted
- MDMA hydrochloride (investigator-led)1 trialPhase 2 authorised
- psilocybin (investigator-led; PEX010 capsules, 25 mg and 5 mg)2 trialsPhase 2 not yet recruiting
- psilocybin (investigator-led; PEX010)1 trialPhase 2 authorised
- psilocybin (investigator-led)2 trialsPhase 2 recruiting
- psilocybin with trazodone (investigator-led; PEX010 25 mg and Trittico)1 trialPhase 2a authorised
- VLS-011 trialPhase 2b complete: NCT06524830 (ELUMINA) COMPLETED on ClinicalTrials.gov, primary completion 2026-07-30 ACTUAL, study completion 2026-10-16 ACTUAL, enrollment 142 ACTUAL, record last updated 2026-10-30, no results posted as of 2026-11-02